Skip to main navigation

Contact Us
Join Us
LinkedIn

Our Company
Our Areas of Focus
- Ophthalmology
  - Diabetic Macular Edema I OCS-01
  - Dry Eye Disease I Licaminlimab
- Neuro-Ophthalmology
  - Optic Neuritis I Privosegtor
  - NAION I Privosegtor
Our Innovation
Investors and Media
- Column
- Column

Our Company
Our Areas of Focus
- Ophthalmology
  - Diabetic Macular Edema I OCS-01 Diabetic Macular Edema I OCS-01
  - Dry Eye Disease I Licaminlimab Dry Eye Disease I Licaminlimab
- Neuro-Ophthalmology
  - Optic Neuritis I Privosegtor Optic Neuritis I Privosegtor
  - NAION I Privosegtor NAION I Privosegtor
Our Innovation
Investors and Media
- Column
- Column

Event Details

Overview
Stock Information
News Releases
Events & Presentations
Governance
Financials
FAQs
Investor Resources
Extra menu
Extra menu
Extra menu

Overview
Stock Information
News Releases
Events & Presentations
Governance
Financials
FAQs
Investor Resources
Extra menu
Extra menu
Extra menu

Q3-2026 Earnings Release

Nov 5, 2026

Visionary Innovation

Our Company
About Us
Governance
Our Culture
Contact Us
Join Us
LinkedIn

Our Areas of Focus
Ophthalmology
Diabetic Macular Edema I OCS-01
Dry Eye Disease I Licaminlimab
Neuro-Ophthalmology
Optic Neuritis I Privosegtor
NAION I Privosegtor

Our Innovation
Pipeline
Clinical Trials
Expanded Access Policy
Science
Publications

Investors and Media
Overview
Stock Information
News Releases
Events & Presentations
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources

© 2026 Oculis All Rights Reserved

Terms of Use
Privacy Notice
Cookie Policy
Expanded Access Policy